Stifel Nicolaus Cuts Outset Medical (NASDAQ:OM) Price Target to $8.00

Outset Medical (NASDAQ:OM) had its target price decreased by Stifel Nicolaus from $14.00 to $8.00 in a report released on Wednesday morning, MarketBeat Ratings reports. Stifel Nicolaus currently has a buy rating on the stock.

OM has been the subject of a number of other reports. BTIG Research restated a “buy” rating and set a $17.00 target price on shares of Outset Medical in a research report on Tuesday, December 16th. Wall Street Zen upgraded Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Outset Medical Price Performance

Shares of NASDAQ:OM opened at $4.56 on Wednesday. Outset Medical has a twelve month low of $3.10 and a twelve month high of $21.98. The company has a current ratio of 7.09, a quick ratio of 5.77 and a debt-to-equity ratio of 0.69. The company has a market cap of $82.76 million, a PE ratio of -0.35 and a beta of 2.07. The company’s 50 day moving average is $5.21 and its 200 day moving average is $11.92.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OM. Legal & General Group Plc acquired a new stake in Outset Medical in the 2nd quarter valued at $34,000. Ameritas Investment Partners Inc. acquired a new position in Outset Medical during the second quarter worth $35,000. BNP Paribas Financial Markets lifted its holdings in Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Outset Medical in the second quarter valued at about $78,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Outset Medical during the second quarter worth about $108,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.